sengenics

Introducing i-Ome® Cancer
Revealing *true* biological insights in cancer research

i-Ome Cancer is the **largest cancer-focused protein microarray on the market**, designed to profile autoantibodies against 500+ antigens simultaneously with exceptional precision. Utilizing proprietary KREX® technology, i-Ome Cancer displays correctly folded proteins for specific antibody binding and enhanced signal clarity.

Discover why autoantibodies are the next-generation biomarkers in cancer precision medicine

Read White Paper

Featured Applications

Identify Cancer Antigens Targeted *In Vivo*

Obtain crucial insights into disease mechanisms and pinpoint therapeutic targets.

Screen Immune Responses for Early Cancer Detection

Uncover autoantibodies to early molecular changes in cancer.

Guide Vaccine and Drug Development

Select the right patients for clinical trials, validate target specificity, and test for off-target drug reactivity.

Comprehensive Antigen Library

Featuring 500+ unique protein antigens and capacity to analyze two antibody isotypes simultaneously (i.e., IgG and IgA *or* IgG and IgM), i-Ome Cancer provides over 2-fold more coverage than its predecessor, delivering deeper and more comprehensive insights into disease.

These antigens were meticulously selected for their significance in cancer, including:

Tissue and Pathway Relevance

Antigens pertinent to numerous cancer types and pathways (see known antigens targeted in specific cancers to the right).

Therapeutic Targets

Antigens currently targeted by monoclonal antibodies and other cancer treatments.

Cytokines and Chemokines

Proteins involved in all major immune-mediated responses to pathogens, tumors, and inflammation.

Cancer-Driver Proteins

Proteins frequently mutated in cancer, driving disease initiation and progression.

Prognostic Indicators

Proteins linked to unfavorable cancer patient outcomes.

Cancer-Testis Antigens

Antigens normally expressed in germ cells but not in adult somatic tissues.

B-cell and Autoantibody Targets

Key players in immune response and cancer progression.

Ectopic Expression

Proteins aberrantly expressed in cancer that trigger antibody production.

Known Antigens by Cancer Type

Breast

ALDOA, ANGPTL4, ANXA1, ANXA2, BIRC5, CCDC110, CCNB1, CCND1, CDK2, CDKN2A, CEP55, CTAG1A, CTAG1B, etc.

Colorectal

ACRBP, ACVR2B, AFP, AKAP4, ANXA1, BIRC5, CCNB1, CCND1, CDKN2A, CTAG1A, CTAG1B, CTAG2, DDX53, etc.

Gastric

BIRC5, CCDC110, CCNB1, CDKN2A, CTAG1B, CTAG2, DOX53, ENO1, EPCAM, ERBB2, HSPA5, IGF2BP1, IGFBP3, etc.

Lung

ACVR2B, ADAM29, ANXA1, ANXA2, BIRC5, BRAF, CCNB1, CDKN2A, CRYAB, CTAG1A, CTAG1B, CTSD, DKK1, etc.

Melanoma

CTAG1A, CTSD, HNRNPA2B1, HSP90AA1, MAGEB4, MLANA, MSN, CTAG1B, TP53, PMEL, etc.

Ovarian

AFP, BIRC5, C1D, CCNA1, CCNB1, CCND1, CDK2, CDKN2A, CTAG1A, CTAG2, CXCL8, EPCAM, EZR, HSP90AA1, HSPA5, etc.

Pancreatic

ANXA1, ANXA2, BIRC5, CALR, CDKN2A, CHGA, CT45A1, CTAG1A, CTAG1B, CTAG2, EGFR, ELF4, ENO1, EZR, etc.

Download the full list of i-Ome Cancer antigens

Download List